Keywords
Ozempic
GLP-1
Type 2 diabetes mellitus
Obesity
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To explore the use of Semaglutide in the treatment for weight loss, to analyze the drug of peripheral action in the control of weight loss, to evidence the low rate of side effects of GLP-1 analogues in the treatment of obesity and to present the importance of the pharmacist in caring for the patient who uses these drugs. Methods: It is an integrative review of the literature on the importance of pharmacological treatment of obesity. The contents used as a filter in the electronic database were Scielo, PubMed, Medline and Lilacs. Results: The review refers to Ozempic, developed for type 2 diabetes mellitus, and currently used as an off-label to treat obesity. It was observed that patients who used this drug for glycemic control had a decreased appetite, and a loss and maintenance of weight. Final considerations: Lifestyle intervention and pharmacotherapy are important approaches to weight loss. This review emphasized the effectiveness, and the low rate of side effects of Semaglutida for Obesity, not only in loss, but in maintaining the weight lost.